A new review brings together the effectiveness, use and knowledge gaps relating to telehealth, mhealth, game-based support, social platforms and patient portals.
By Prof Jane Speight
Category: Technologies
Diabetes and apps
ACBRD (Dr Steve Trawley, Ms. Shaira Baptista and Prof Jane Speight) have recently published a conceptual follow-up to their 2016 paper that looked at mobile health applications (app) use for self-management support amongst adolescents with type 1 diabetes.
By Dr Steven Trawley
Mobile health for prevention of type 2 diabetes in India
Visiting PhD candidate discusses her research.
by Shruti Muralidharan – PhD candidate from Deakin University’s Global Obesity Centre (GLOBE)
Insulin vs pumps: The REPOSE trial findings deliver a verdict
The much-anticipated findings of the NIHR-funded REPOSE trial were published in The BMJ on 30 March. REPOSE was a cluster-randomised trial designed to investigate the ‘Relative Effectiveness of insulin Pump treatment Over multiple daily injections and Structured Education’.
A study of 1,503 adults with type 1 diabetes measured barriers to device uptake (insulin pump and continuous blood glucose monitors (CGM)) and compared the profiles of device users versus nonusers. For the whole sample, from a list of 19, the three most commonly endorsed barriers to diabetes device uptake were ‘cost of supplies’ (61%), ‘cost of device’ (57%) and ‘insurance coverage’ (57%), all of which were deemed to be ‘non-modifiable’ barriers by the authors. The top three commonly endorsed ‘modifiable’ barriers were ‘hassle of wearing devices all of the time’ (47%), ‘do not like having diabetes devices on my body’ (35%) and ‘do not like how diabetes devices look on my body’ (26%).
Read more